Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Stadsporten City Gate AB
Mandate

Vinge advises Stadsporten City Gate AB

May 03, 2013

Vinge has advised Stadsporten City Gate AB in connection with the sale of the company’s 70.4% shareholding in Morningstar Sweden AB to Morningstar Inc. Morningstar’s service offering in Sweden includes Morningstar Direct, investment data, internet-based tools and Morningstar.se, a website containing fund information for the general public.

Since its formation in 1997, Citygate has acted as a development company concentrating on media services and the Internet. Citygate is owned by the media groups, Eskilstuna-Kuriren AB, Mediabolaget Västkusten AB, MittMedia AB, Norrköpings Tidningars Media AB, Sydsvenska Dagbladet AB, Tidnings AB Promedia i Mellansverige and Västerbottens-Kuriren AB.

Vinge’s team consisted of partner Bo Adrianzon together with associates Johan Mattsson and Filip Öhrner.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024